The efficacy of Yiqi Huoxue method in treating coronary artery disease after percutaneous coronary intervention: A meta-analysis in accordance with PRISMA guideline

Medicine (Baltimore). 2022 Oct 14;101(41):e30739. doi: 10.1097/MD.0000000000030739.

Abstract

Background: Percutaneous coronary intervention (PCI), the most common method in treating coronary artery disease (CAD), has a variety of side effects. Yiqi Huoxue therapy (YQHX) can effectively alleviate the symptoms of patients and reduce the side effects. However, a reliable and systematic assessment of the methodologies is not available.

Methods: Seven electronic databases were searched to identify randomized controlled trials of YQHX method for CAD after PCI. The quality assessment of the trials included was performed by employing the Cochrane Risk of Bias tool.

Results: One thousand eight hundred sixty-eight patients from 23 randomized controlled trials were included in this review. The aggregated results showed that the experimental group got better effect in increasing ORR, TCMSRR, ECG, HDL-C, and in lowering the level of CRP, TC, and MACE in comparison with the control group.

Conclusion: YQHX method is a valid complementary and alternative therapy in the management of CAD after PCI, and is an effective and safe therapy for CAD.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Coronary Artery Disease* / diagnosis
  • Coronary Artery Disease* / drug therapy
  • Humans
  • Percutaneous Coronary Intervention* / methods
  • Randomized Controlled Trials as Topic
  • Research Design